Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
J Thromb Haemost. 2017 Jun;15(6):1065-1077. doi: 10.1111/jth.13690. Epub 2017 May 9.
Essentials The widely recommended CHA2DS2-VASc shows conflicting results in contemporary validation studies. We performed a systematic review and meta-analysis of 19 studies validating CHA2DS2-VASc. There was high heterogeneity in stroke risks for different CHA2DS2-VASc scores. This was not explained by differences between setting of care, or by performing meta-regression.
Background The CHA2DS2-VASc decision rule is widely recommended for estimating stroke risk in patients with atrial fibrillation (AF), although validation studies show ambiguous and conflicting results. Objectives To: (i) review existing studies validating CHA2DS2-VASc in AF patients who are not (yet) anticoagulated; (ii) meta-analyze estimates of stroke risk per score; and (iii) explore sources of heterogeneity across the validation studies. Methods We performed a systematic literature review and random effects meta-analysis of studies externally validating CHA2DS2-VASc in AF patients not receiving anticoagulants. To explore between-study heterogeneity in stroke risk, we stratified studies to the clinical setting in which patient enrollment started, and performed meta-regression. Results In total, 19 studies were evaluated, with over two million person-years of follow-up. In studies recruiting AF patients in hospitals, stroke risks for scores of 0, 1 and 2 were 0.4% (approximate 95% prediction interval [PI] 0.2-3.2%), 1.2% (95% PI 0.1-3.8%), and 2.2% (95% PI 0.03-7.8%), respectively. These were consistently higher than those in studies recruiting patients from the open general population, with risks of 0.2% (95% PI 0.0-0.9%), 0.7% (95% PI 0.3-1.2%) and 1.5% (95% PI 0.4-3.3%) for scores of 0, 1, and 2, respectively. Heterogeneity, as reflected by the wide PIs, could not be fully explained by meta-regression. Conclusions Studies validating CHA2DS2-VASc show high heterogeneity in predicted stroke risks for different scores.
(i)回顾现有的、用于验证非抗凝治疗的房颤患者的 CHA2DS2-VASc 决策规则的验证研究;(ii)对每个评分的卒中风险进行荟萃分析;(iii)探索验证研究中异质性的来源。
我们对非抗凝治疗的房颤患者的 CHA2DS2-VASc 外部验证研究进行了系统文献回顾和随机效应荟萃分析。为了探索卒中风险的研究间异质性,我们根据患者入组的临床环境对研究进行分层,并进行了荟萃回归分析。
共评估了 19 项研究,随访超过两百万人年。在招募医院就诊的房颤患者的研究中,评分 0、1 和 2 的卒中风险分别为 0.4%(近似 95%预测区间[PI]为 0.2-3.2%)、1.2%(95%PI 为 0.1-3.8%)和 2.2%(95%PI 为 0.03-7.8%)。这些风险明显高于从开放的普通人群中招募患者的研究,其评分 0、1 和 2 的风险分别为 0.2%(95%PI 为 0.0-0.9%)、0.7%(95%PI 为 0.3-1.2%)和 1.5%(95%PI 为 0.4-3.3%)。异质性,反映在宽的 PI 中,不能完全通过荟萃回归来解释。
验证 CHA2DS2-VASc 的研究在不同评分的预测卒中风险方面存在很大的异质性。